Table 3.

Vildagliptin add-on to metformin studies contributing to analyses

Study No.	Study description		Randomized patients	Treatment duration (weeks)	Publication
1	Placebo-controlled efficacy/safety study in T2DM patients inadequately controlled with metformin (HbA1c 7.5–11%)		544	24	[15]
2	Active-controlled (glimepiride) long-term efficacy/safety study in T2DM patients treated with metformin (HbA1c >6.5–8.5%)		3,118	≥104	[16, 34]
3	Active-controlled (gliclazide) long-term efficacy/safety study in T2DM patients inadequately controlled with metformin (HbA1c 7.5–11%)		1,007	52	[17]
4	Active-controlled (pioglitazone) long-term efficacy/safety study in T2DM patients inadequately controlled with metformin (HbA1c 7.5–11%)		576	52	[18, 35]

HbA _1c hemoglobin A_1c, T2DM type 2 diabetes mellitus